

**Name: Yael Dishon Benattar**

**Date: Nov. 2022**

## **PART A: CURRICULUM VITAE**

### **1. Personal Details**

<b>E-mail Address:</b>	ydishon@staff.haifa.ac.il
------------------------	---------------------------

### **2. Summary of my Scientific and Other Contributions and Future Plans**

#### **a. Contributions to Science:**

##### **1. Research activities for optimizing antibiotic treatment for multidrug resistant Gram-negative organisms**

My M.A thesis focused on an old antimicrobial agent, Colistin, which was abandoned in the '70s due to low efficacy and high toxicity, and returned into use as a "last resort" drug around 2008, with the emergence of a new global threat - Carbapenem-resistant Gram-negative bacteria. My research assessed the efficacy and toxicity of high vs. low doses of Colistin for the treatment of invasive infections caused by the latter bacteria. Within my position as a research assistant at the Infectious Diseases Institute, Rambam Health Care Campus, I also acted as the study coordinator of a European Union funded, multicenter, randomized controlled trial (within the AIDA Project). The trial aimed at assessing the efficacy of antibiotic treatment with colistin as monotherapy vs. in combination with Meropenem for similar types of infections. One of the salient findings of both studies was the high mortality rate among these cohorts of patients, which ranges between 42%-45%.

Relevant publications: C1, C5, C9, C10

##### **2. Antibiotic treatment and antibiotic stewardship at end-of-life**

My M.A. thesis along with my daily work with terminally ill study participants, paved the way to my Ph.D. research, which focused on developing and testing a cost-benefit model for reducing futile antibiotic treatment at end-of-life, within a Computerized Decision Support System. It also consisted of a survey to assess healthcare professionals' (physicians, nurses, social workers) attitudes towards various interventions at end-of-life, with specific focus on antibiotic treatment. The survey also compared between attitudes towards similar

interventions in two distinct conditions; advanced dementia vs. other end-of-life conditions. Distribution of the survey evoked a discourse among the participating health care professionals regarding the dilemmas involved in treatments at end-of-life. The research provided me with a broader perspective on the legal, ethical and clinical challenges involved.

Relevant publications: J1, J2 (under submission process)

**b. Contribution to Society:**

My position as a community nurse in two rural clinics, and later, as a Head Nurse in a Primary Health Care Clinic, complied with my interest in end-of-life care, as I was attending and supporting both patients in terminal conditions and their caregivers. I found interest both in the clinical aspect of palliative care as well as the social and personal aspects. The individual, even intimate, encounter with patients and caregivers, exposed me to different preferences and coping strategies of both. It enabled me to practice nursing the way I envision it – meaningful for patient and caregiver/family, personally tailored yet professional. Further research may strengthen evidence-based palliative care in clinical practice.

**c. Plans for future research programs (my academic vision):**

My future plans are to continue end-of-life research in various settings. I will focus on obstacles, dilemmas and challenges in delivering palliative care and practicing palliative approach in acute care setting, in order to plan, implement and assess interventions to promote the latter, addressing mainly staff members. In community and long-term care setting, where autonomy plays a major role in end-of-life care planning, including advance directives, I wish to address mainly patients/public and caregivers. I plan to further investigate the possible differences in palliative approach and palliative care in advance dementia, versus other end-of-life conditions.

Along with researching, I wish to deliver nursing education focusing on end-of-life and palliative care, both becoming cardinal in the contemporary discourse. Within this scope, I wish to emphasize on research. Throughout my professional and academic experience, I have realized the importance of research in nursing, and the involvement of nursing staff in research in general. I believe in providing nursing staff not only with clinical knowledge and skills, but also with academic skills; the increasing spectrum of nursing profession requires variety of educational programs, both clinical and academic.

I believe my clinical experience in primary care at the community, experience in clinical research and various research methods, proximity to a clinical field and my comprehensive clinical knowledge gained during years of clinical research, will be beneficial to my future position as a faculty.

### 3. Higher Education

#### a. Undergraduate and Graduate Studies

<b>Period of Study</b> (month/year – month/year)	<b>Name of Institution and Department</b>	<b>Degree</b>
10/1996-9/1999	University of Haifa, English Language and Literature	B.A.
10/2012-12/2014	University of Haifa, The Cheryl Spencer Department of Nursing	M.A. (Dean's honor)
10/2015-8/2020	University of Haifa, The Cheryl Spencer Department of Nursing	Ph.D.

#### b. Post-Doctoral Studies

<b>Period of Study</b> (month/year – month/year)	<b>Name of Institution and Department/Lab</b>	<b>Name of Host</b>
2/2021-9/2022	Technion, Israel Institute of Technology, The Ruth and Bruce Rappaport Faculty of Medicine, Department of Immunology	Prof. Shai Shen-Orr

### 4. Academic Ranks and Tenure in Institutes of Higher Education

<b>Period</b> (month/year – month/year)	<b>Name of Institution and Department</b>	<b>Rank/Position</b> Specify if full or percent part time
10/2020 - 03/2021	The Academic College of Tel Aviv-Yaffo, School of Nursing Science	Lecturer; teaching a 2 credit-points course "Critical thinking"

### 5. Offices in Academic Administration

<b>Years</b>	<b>Name of Institution and Department</b>	<b>Role</b>
6/2014-2/2016	University of Haifa, The Cheryl Spencer Department of Nursing	Research assistant with Prof. Cheryl Zlotnick

### 6. Scholarly Positions and Activities outside the University

<b>Year</b>	<b>Reviewing for Refereed Journals</b>
2017, 2022	Clinical Microbiology and Infections [I.F 8.067, 13/136, Q1 (Microbiology), 5/93, Q1 (Infectious Diseases)]

<b>Year</b>	<b>Other Scholarly Positions and Activities</b>
2011-present	“Prognosa” - Developing an on-line pharmaceutical calculation question pool, providing an ongoing support for nursing students
2012-present	Rambam Health Care Campus, Institute for Infectious Diseases - Guidance of MD projects: Instructing medical students on data collection and assistance in statistical analysis

<b>Year</b>	<b>Other Relevant Positions and Activities</b>
2000-2001	Rafael Armaments Development Authority; Project Secretary. POC with customers abroad
2001-2003	Rafael Armaments Development Authority; Buyer, Purchasing Department
6/2005-12/2006	Clalit Healthcare Services, Rural Clinics, Carmel Beach; Registered Nurse
9/2007- 12/2010	Clalit Healthcare Services, Primary Health Care Clinic, Kiryat Amal; Head Nurse
10/2012-present	Infectious Diseases Institute, Rambam Health Care Campus; Research coordinator/ research assistant

## **7. Conferences / Invited Lectures / Seminars (last 10 years or more)**

### **a. Participation in International Conferences**

<b>Date</b> (month/year)	<b>Name of Conference</b>	<b>Place of Conference</b> (city & country)	<b>Subject of Lecture/Discussion</b>	<b>Role</b>
06/ 2015	The Annual Conference of the Israeli Society for Infectious Diseases	Ramot, Israel	“The safety and effectiveness of high-dose colistin: prospective observational study”	Oral presentation (presenter)
9/2015	The 2nd International	San Diego, USA	“The safety and effectiveness of high-	Oral presentation

<b>Date</b> (month/year)	<b>Name of Conference</b>	<b>Place of Conference</b> (city & country)	<b>Subject of Lecture/Discussion</b>	<b>Role</b>
	Conference on Polymyxins		dose colistin: prospective observational study”	(presenter)
6/2017	Dementia Workshop, Minerva Center for the Interdisciplinary Study of End of Life, Tel Aviv University	Kibbutz Zova, Israel	Antibiotic treatment for patients with dementia and other terminal conditions: a survey among health care professionals”	Oral presentation (presenter)
9/2017	The D. Dan and Betty Kahn 6th Annual Scientific Symposium for the Michigan-Israel Partnership for Research and Education	Haifa, Israel	“Colistin alone vs. colistin plus meropenem against carbapenem-resistant Gram-negative bacteria”	Poster presentation (presenter)
4/2018	28th ECCMID (European Congress of Clinical Microbiology and Infectious Diseases)	Madrid, Spain	“The association between empirical antibiotic treatment and mortality in severe infections caused by carbapenem-resistant Gram-negative bacteria: a prospective study”	Poster presentation (presenter)
4/2018	28th ECCMID (European Congress of Clinical Microbiology and Infectious Diseases)	Madrid, Spain	“Reducing futile antibiotic treatment using a computerized decision-support system”	Poster presentation (presenter)
4/2018	28th ECCMID (European Congress of Clinical Microbiology and Infectious Diseases)	Madrid, Spain	“Colistin population pharmacokinetics (PK) in 324 critically ill patients included in the AIDA colistin study”	Poster presentation (co-author)

<b>Date</b> (month/year)	<b>Name of Conference</b>	<b>Place of Conference</b> (city & country)	<b>Subject of Lecture/Discussion</b>	<b>Role</b>
4/2018	The 3rd International Conference on Polymyxins	Madrid, Spain	“Colistin population pharmacokinetics (PK) in 324 critically ill patients included in the AIDA colistin study”	Oral presentation (co-author)
4/2019	29th ECCMID (European Congress of Clinical Microbiology and Infectious Diseases)	Amsterdam, The Netherlands	“In vitro synergy does not predict treatment outcome with colistin plus meropenem in patients with carbapenem-resistant gram-negative infections”	Poster presentation (co-author)
9/2018	24th World Congress on Medical Law and Ethics	Tel-Aviv, Israel	“Cost-Benefit Model for Antibiotic Treatment at End of Life”	Oral presentation (presenter)
4/2020	30th ECCMID (European Congress of Clinical Microbiology and Infectious Diseases)	Paris, France	“Introducing end-of-life considerations into a computerized decision support system for antibiotic treatment: effects on the system's recommendations and comparison to physicians' behavior”	Abstract accepted for poster presentation (presenter); conference was cancelled due to COVID-19 outbreak
4/2022	32th ECCMID (European Congress of Clinical Microbiology and Infectious Diseases)	Lisbon, Portugal	"Population external validity of a randomized controlled trial on duration of antibiotics: under-representation of patients with cognitive and functional impairment"	Poster presentation (co-author)
4/2022	32th ECCMID (European Congress of Clinical Microbiology and Infectious Diseases)	Lisbon, Portugal	"Similarity between included and excluded patients in an investigator-initiated randomized controlled trial with restricted exclusion criteria in	Poster presentation (co-author)

<b>Date</b> (month/year)	<b>Name of Conference</b>	<b>Place of Conference</b> (city & country)	<b>Subject of Lecture/Discussion</b>	<b>Role</b>
			infectious diseases: can it be achieved?"	

**b. Participation in Local Conferences**

<b>Date</b> (month/year)	<b>Name of Conference</b>	<b>Place of Conference</b> (city)	<b>Subject of Lecture/Discussion</b>	<b>Role</b>
4/2016	The End-of-Life Meeting, The Hebrew University	Jerusalem	“Choosing wisely antibiotic treatment to reduce futile therapy at end of life: cost-benefit model development”	Oral presentation (presenter)

**c. Invited Scholarly Lectures (other than in conferences) N/A**

**c.1. Abroad**

<b>Year</b>	<b>Name of Forum</b>	<b>Place of Lecture</b> (institute, city, country)	<b>Subject of Lecture</b>	<b>Role</b>

**c.2. In Israel**

<b>Year</b>	<b>Name of Forum</b>	<b>Place of Lecture</b> (institute, city)	<b>Subject of Lecture</b>	<b>Role</b>

**d. Colloquium or Seminar Talks**

<b>Year</b>	<b>Name of Forum</b>	<b>Place of Lecture</b> (institute, city, country)	<b>Subject of Lecture</b>
2013	Preserving old antibiotics for the future –	Rome, Italy	Researchers Meeting - scientific updates and

	International AIDA Project meeting		discussions re antibiotic treatments, resistance and stewardship
2014	Preserving old antibiotics for the future – International AIDA Project meeting	Vienna, Austria	Researchers Meeting - scientific updates and discussions re antibiotic treatments, resistance and stewardship
2015	Preserving old antibiotics for the future – International AIDA Project meeting	Warsaw, Poland	Researchers Meeting - scientific updates and discussions re antibiotic treatments, resistance and stewardship
2016	Preserving old antibiotics for the future – International AIDA Project meeting	Hague, The Netherlands	Researchers Meeting - scientific updates and discussions re antibiotic treatments, resistance and stewardship
2017	JPI-EC-AMR :Dynamics of Antimicrobial Resistance in the Urban Water Cycle in Europe (DARWIN) – Project Team	Copenhagen, Denmark	Researchers Meeting – Start up meeting, scientific discussions
2019	Infectious Diseases teams: Rambam Health Care Campus, Rabin Medical Center (Beilinson Campus), Radboud University	Rabin Medical Center (Beilinson Campus), Petah Tikva, Israel	Antibiotic Stewardship: Practice and Research - Researchers Meeting

**e. Organization of Conferences or Sessions**

<b>Year</b>	<b>Name of Conference</b>	<b>Place of Conference</b> (city and country)	<b>Subject of Conference</b>	<b>Role</b>

**8. Research Grants**

**a. Grants Awarded**



<b>Years</b>	<b>Role in Research</b> (PI, Co-PI, CI)	<b>Other Researchers</b> (Name & Role)	<b>Title</b>	<b>Funded by</b>	<b>Amount</b>	<b>Relevant Publications</b>
2017	Co-PI	PI: Prof. Mical Paul	Choosing wisely antibiotic treatment to reduce futile therapy: cost benefit model development	Gassner Fund for Medical Research (C)	Total 80,000 NIS	

**b. Submission of Research Proposals - Pending**

<b>Years</b>	<b>Role in Research</b> (PI, Co-PI, CI)	<b>Other Researchers</b> (Name & Role)	<b>Title</b>	<b>Funds Requested Agency</b>	<b>Amount</b>
2021	Co-PI	PI: Mical Paul, MD  Co-PIs: Marina Raines, MD  Khetam Hussein, MD  Safwat Zidat, MD  Yousef Takrouri, MD  Dafna Yahav, MD  Leonard Leibovici, MD	Control the drug-resistant bacteria and Israel and Palestine: a cluster-randomized trial (C)	Unites States Agency International Development (USAID) Middle East Regional Cooperation (MERC) Program	581,775.6 USD

**c. Submission of Research Proposals – Not funded**

<b>Years</b>	<b>Role in Research</b>	<b>Other Researchers</b>	<b>Title</b>	<b>Funds Requested Agency</b>
--------------	-------------------------	--------------------------	--------------	-------------------------------

	(PI, Co-PI, CI)	(Name & Role)		
2021	Co-PI	PI: Mical Paul, MD	An Integrated Antibiotic Stewardship Program Using a Computerized Decision Support System (C)	Pfizer – Global Medical Grants 99,866 USD

## 9. Scholarships, Awards and Prizes

Years	Name of Award	Other Awardees	Purpose of Award or Achievement	Source
2014	Scholarship for Excellence in Studies (10,000 NIS)		Outstanding achievements	Graduate Studies Authority, University of Haifa
2015	Distinguished Thesis Award		Master's Thesis	Dean, Graduate Studies Authority, University of Haifa
2015-2018	Advanced Studies scholarship for research students (Total 132,000 NIS)		Outstanding doctoral candidates	Graduate Studies Authority, University of Haifa
2018	Conference Participation Grant (1,600 NIS)		Research support	Graduate Studies Authority, University of Haifa
2018	Research Support Grant (10,000 NIS)		Research support	The Cheryl Spencer Institute of Nursing Research

## 10. Teaching

### a. Courses Taught (last 10 years)

Years	Name of Course	Type of Course Lecture/Seminar/ Workshop/ Online Course/ Introduction Course (Mandatory)	Level BA/BSc/MA/MSc/ PhD/ etc
10/2020 - 03/2021	Critical Thinking	Introduction Course (Mandatory)	B.A.

### b. Supervision of Graduate Students (for Full Professor – only last 10 years) N/A

Name of Student	Name of Other Mentors	Title of Thesis	Degree	Year of Completion / in Progress	Student's Achievements
<b>Master's Students</b>					
<b>Ph.D. Students</b>					
<b>Post-Doctoral Fellows</b>					

## 11. Miscellaneous

### a. Further training and education

Period of Study	Name of Institution and Department	Degree
1/2012 - 3/2013	Rambam Health Care Campus, Advanced Training Center.	Emergency Ward Training
2003-2005	Schoenbrun Nursing School, Ichilov Medical Center, Tel Aviv. Nursing Studies, Accelerated Nursing Program	R.N.

### b. Voluntary activities

Period	Name of Institution and department	Function
--------	------------------------------------	----------

2/2018- 1/2019	“Haifa Grad Team”, Excellent PhD students at the University of Haifa.	Team member
----------------	---	-------------

## PART B: PUBLICATIONS

<b>H-index:</b>	8	<b>Source:</b> Google Scholar
<b>Citation index:</b>	665	<b>Source:</b> Google Scholar
<b>ORCID number:</b>	0000-0002-9646-5376	
<b>Google Scholar link:</b>	<a href="https://scholar.google.com/citations?user=Fz3rVEUAAAAJ&amp;hl=en">https://scholar.google.com/citations?user=Fz3rVEUAAAAJ&amp;hl=en</a>	

### A. Ph.D. Dissertation

<b>Title:</b>	Choosing wisely antibiotic treatment to reduce futile therapy at end of life: Cost-benefit model development and testing
<b>Date of submission:</b>	12/2019
<b>Number of pages:</b>	141
<b>Language:</b>	English
<b>Name of supervisor:</b>	Prof. Efrat Dagan, Prof. Mical Paul
<b>University:</b>	University of Haifa
<b>Publications:</b> item no. from the following list (for example: B2, D12, etc.)	

### B. Scientific Books (Refereed) N/A

- a. **Authored Books**
- b. **Monographs**
- c. **Edited Books and Special Journal Issues**

### C. Articles in Refereed Journals

#### Published

1. **Dishon Benattar Y**, Omar M, Zusman O, Yahav D, Zak-Doron Y, Altunin S, Elbaz M, Daitch V, Granot M, Leibovici L, Paul M (2016). The Effectiveness and Safety of High-Dose Colistin: Prospective Cohort Study. *Clinical Infectious Diseases*. 63(12):1605-1612 I.F. 8.216, 4/84, Q1 (Infectious Diseases), 15/151 (Immunology), 8/114 (Microbiology)]. 52 Citations.
2. Zusman O, Altunin S, Koppel F, **Dishon Benattar Y**, Gedik H, Paul M (2017). Polymyxin monotherapy or in combination against carbapenem-resistant bacteria:

systematic review and meta-analysis. *Journal of Antimicrobial Chemotherapy*. 72(1):29-39. [I.F 5.071, 9/84, Q1 (Infectious Diseases), 20/125 (Microbiology), 23/257 (Pharmacology & Pharmacy)]. 129 Citations.

3. Zlotnick C, Birenbaum-Carmeli D, Goldblatt H, **Dishon Y**, Taychaw O, Shadmi E (2017). Adolescent immigrants, the impact of gender on health status. *European Journal of Public Health*. 27(3): 453-459. [I.F 2.431, 54/176, Q2 (Public, Environmental and Occupational Health)]. 4 Citation.
4. Zlotnick C, Birenbaum-Carmeli D, Goldblatt H, **Dishon Y**, Taychaw O, Shadmi E. (2018). Social Gradient and Heterogeneity in Adolescent Immigrants' Health Risk and Healthcare Experiences. *European Journal of Pediatrics*. 177(2): 221-228. [I.F 1.921, 53/121, Q2 (Pediatrics)]. 3 Citations.
5. Paul M, Daikos G L, Durante Mangoni E, Yahav D, Carmeli, **Dishon Benattar Y**, Skiada A, Andini R, Eliakim-Raz N, Nutman A, Zusman O, Antoniadou A, Pafundi P C, Adler A, Dickstein Y, Pavleas I, Zampino R, Daitch V, Bitterman R, Zayyad H, Koppel F, Levi I, Babich T, Friberg LE, Mouton JW, Theuretzbacher U, Leibovici L (2018). Colistin alone versus colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: Multicentre open-label randomized controlled trial. *Lancet Infectious Diseases*. 18(4):391-400. [I.F 19.864, 1/84, Q1 (Infectious Diseases)]. 306 Citations.
6. Zak-Doron Y, **Dishon Benattar Y**, Pfeffer I, Daikos GL, Skiada A, Antoniadou A, Durante-Mangoni E, Andini R, Cavezza G, Leibovici L, Yahav D, Eliakim-Raz N, Carmeli Y, Nutman A, Paul M; AIDA Study Group (2018). The Association Between Empirical Antibiotic Treatment and Mortality in Severe Infections Caused by Carbapenem-resistant Gram-negative Bacteria: A Prospective Study. *Clinical Infectious Diseases*. 67(12):1815-1823. [I.F. 8.216, 4/84, Q1 (Infectious Diseases), 15/151 (Immunology), 8/114 (Microbiology)] .27 Citations.
7. Dickstein Y, Lellouche J, Dalak Amar MB, Schwartz D, Nutman A, Daitch V, Yahav D, Leibovici L, Skiada A, Antoniadou A, Daikos GL, Andini R, Zampino R, Durante-Mangoni E, Mouton JW, Friberg LE, **Benattar YD**, Bitterman R, Neuberger A, Carmeli Y, Paul M (2019). Treatment outcomes of colistin and carbapenem-resistant *Acinetobacter baumannii* infections: an exploratory subgroup analysis of a randomized clinical trial. *Clinical Infectious Diseases*. 69(5):769-776 [I.F. 8.216, 4/84, Q1 (Infectious Diseases), 15/151 (Immunology), 8/114 (Microbiology)]. 65 Citations.
8. Zlotnick C, Birenbaum-Carmeli D, Goldblatt H, **Dishon Y**, Taychaw O, Shadmi E. (2019). The Impact of Adolescents' Racial and Ethnic Self-Identity on Hope. *Health & Social Care in the Community*. 27(5): e705-715. [I.F 2.039, 47/157, Q2 (Public, Environmental & Occupational Health), 7/42, Q1 (Social Work)]. 2 Citations.
9. Dickstein Y, Lellouche J, Schwartz D, Nutman A, Rakovitsky N, **Dishon Benattar Y**, Altunin S, Bernardo M, Iossa D, Durante-Mangoni E, Antoniadou A, Skiada A, Deliolanis I, Daikos GL, Daitch V, Yahav D, Leibovici L, Rognås V, Friberg LE, Mouton JW, Paul M, Carmeli Y; AIDA study group (2019). Colistin Resistance Development Following Colistin-Meropenem Combination Therapy vs. Colistin Monotherapy in Patients with Infections Caused by Carbapenem-Resistant Organisms.

Clinical Infectious Diseases. 71(10):2599-2607. [I.F. 8.216, 4/84, Q1 (Infectious Diseases), 15/151 (Immunology), 8/114 (Microbiology)]. 8 Citations.

10. Kristoffersson AN, Brill MJ, Rognås V, **Dishon Y**, Durante-Mangoni E, Daitch V, Skiada A, Lellouche J, Nutman A, Kotsaki A, Andini R, Eliakim-Raz N, Bitterman R, Antoniadou A, Karlsson MO, Theuretzbacher U, Leibovici L, Daikos GL, Mouton JW, Carmeli Y, Paul M, Friberg LE (2020). Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteria. *Clinical Microbiology and Infection*. 26(12):1644-1650 [I.F 8.067, 13/136, Q1, (Microbiology), 5/93, Q1 (Infectious Diseases)]. 8 Citations.
11. Nutman A, Lellouche J, Temkin E, Daikos GL, Skiada A, Durante-Mangoni E, **Dishon-Benattar Y**, Bitterman R, Yahav D, Daitch V, Bernardo M, Iossa D, Zusman O, Friberg LE, Mouton JW, Theuretzbacher U, Leibovici L, Paul M, Carmeli Y, AIDA Study Group (2020). Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes. *Clinical Microbiology and Infection*. 26(9):1185-1191. [I.F 8.067, 13/136, Q1, (Microbiology), 5/93, Q1 (Infectious Diseases)]. 21 Citations.
12. Daitch V, Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, **Benattar YD**, Skiada A, Andini R, Eliakim-Raz N, Nutman A, Zusman O, Antoniadou A, Cavezza G, Adler A, Dickstein Y, Pavleas I, Zampino R, Bitterman R, Zayyad H, Koppel F, Zak-Doron Y, Levi I, Babich T, Turjeman A, Ben-Zvi H, Friberg LE, Mouton JW, Theuretzbacher U, Leibovici L. Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity (2021). *BMC Infectious Diseases* 21:309. [I.F 3.090, 57/93, Q3 (Infectious Diseases)]. 0 Citations.
13. Nutman A, Temkin E, Lellouche J, Rakovitsky N, Hameir A, Daikos G, Durante-Mangoni E, Pavleas I, **Dishon Y**, Petersiel N, Yahav D, Eliakim N, Bernardo M, Iossa D, Friberg LE, Theuretzbacher U, Leibovici L, Paul M, Carmeli Y; AIDA Study Group (2022). In vivo fitness of carbapenem-resistant *Acinetobacter baumannii* strains in murine infection is associated with treatment failure in human infections. *Clinical Microbiology and Infection* 28(1):73-78. [I.F 8.067, 13/136, Q1 (Microbiology), 5/93, Q1 (Infectious Diseases)]. 0 Citations.
14. Frenk S, Temkin E, Lurie-Weinberger M, Keren-Paz A, Rov R, Rakovitsky N, Wullfhart L, Nutman A, Daikos G, Skiada A, Durante-Mangoni E, **Dishon Benattar Y**, Bitterman R, Yahav D, Daitch V, Bernardo M, Iossa D, Zusman O, Friberg L, Mouton J, Theuretzbacher U, Leibovici L, Geffen, Y, Gershon, R, Paul M, Carmeli Y. Large scale whole genome sequencing of carbapenem-resistant *Acinetobacter baumannii* isolates reveals patterns of dissemination of ST clades associated with antibiotic resistance. *Journal of Antimicrobial Chemotherapy*. 2022 Jan 25:dkac010. doi: 10.1093/jac/dkac010. Online ahead of print. [I.F 5.790, 14/93, Q1 (Infectious Diseases), 26/136 (Microbiology), 42/275 (Pharmacology & Pharmacy)]. 0 Citations.
15. Turjeman A, Koppel F, Franceschini E, Yahav D, Dolci G, Bacca E, Babich T, Khazem E, Baum E, Nassar R, Bitterman R, **Dishon-Benattar Y**, Hassoun-Kheir N, Santoro A, Eliakim-Raz N, Poran I, Pertzov B, Stern A, Dickstein Y, Maroun E, Raines M, Meschiari M, Bishara J, Goldberg E, Venturelli C, Sarti M, Mussini C, Paul M, Leibovici L. External validity of a randomized controlled trial on duration of antibiotics

for the treatment of Gram-negative bacteremia. *Gerontology*. 2022 Oct. Online ahead of print. [I.F 5.597, 17/54, Q2 (Geriatrics and Gerontology)].

#### Accepted for publication

1. Turjeman A, von Dach E, Molina J, Franceschini E, Koppel F, Yelin D, Dishon-Benattar Y, Mussini C, Rodríguez-Baño J, Cisneros JM; Huttner A, Paul M, Leibovici L, Yahav D. Duration of antibiotic treatment for Gram-negative bacteremia – systematic review and individual participant data (IPD) meta-analysis. *eClinical Medicine*. Nov. 2022 [I.F 17.03, 13/329, Q1 (Medicine, General & Internal)]. 0 Citations.

#### D. Articles or Chapters in Scientific Books (Refereed)

#### E. Articles in Conference Proceedings

#### F. Entries in Encyclopedias

#### G. Other Scientific Publications

#### Published

1. Dickstein Y, Leibovici L, Yahav D, Eliakim-Raz N, Daikos GL, Skiada A, Antoniadou A, Carmeli Y, Nutman A, Levi I, Adler A, Durante-Mangoni E, Andini R, Cavezza G, Mouton JW, Wijma RA, Theuretzbacher U, Friberg LE, Kristoffersson AN, Zusman O, Koppel F, **Dishon Benattar Y**, Altunin S, Paul M; AIDA consortium (2016). Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol. *BMJ Open*. 6(4). [I.F 2.369, 38/155, Q1 (Medicine, General & Internal)]. 42 Citations.
2. Paul M, Yahav D, **Dishon-Benattar Y**, Leibivici L (2017). Reply to Zavascki and Nation. *Clinical Infectious Diseases*. 64(5):696. [I.F. 8.216, 4/84, Q1 (Infectious Diseases), 15/151 (Immunology), 8/114 (Microbiology)].
3. Liu J, Tong SYC, Davis JS, Rhodes NJ, Scheetz MH; CAMERA2 Study Group\*. Vancomycin Exposure and Acute Kidney Injury Outcome: A Snapshot From the CAMERA2 Study. *Open Forum Infect Dis*. 2020 Nov 4;7(12):ofaa538. [IF 3.835, 92/162 Q3 (Immunology), 56/136, Q2 (Microbiology), 37/93, Q2 (Infectious Diseases)]. 10 Citations. (\*A member of study group)
4. Tong SYC, Lye DC, Yahav D, et al\*. Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal  $\beta$ -Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized



Clinical Trial. Journal of the American Medical Association. 2020;323(6):527–537. [IF 56.274, 3/167 Q1 (Medicine, General & Internal)]. 98 Citations. (\* Additional contributor)

5. ISARIC Clinical Characterization Group\*. COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study. *Infection*. 2021 Oct;49(5):889-905. Epub 2021 Jun 25. [IF 3.553, 46/92 Q2 (infectious diseases)]. 6 Citations. (\*A member of study group)
6. ISARIC Clinical Characterisation Group\*, Hall MD, Baruch J, Carson G, Citarella BW, Dagens A, Dankwa EA, Donnelly CA, Dunning J, Escher M, Kartsonaki C, Merson L, Pritchard M, Wei J, Horby PW, Rojek A, Olliaro PL. Ten months of temporal variation in the clinical journey of hospitalised patients with COVID-19: An observational cohort. *eLife*, 10, e70970. <https://doi.org/10.7554/eLife.70970>. [IF 8.713, 8/94 Q1 (biology)]. 1 Citation. (\*A member of study group)

## H. Other Works and Publications

### I. Submitted for Publication

#### a. Books

#### b. Articles

#### c. Chapters in Scientific collections/books

### J. Publications in Preparation

#### a. Books

#### b. Articles

1. **Dishon-Benattar Y**, Dagan E, Shbita R, Zak-Doron Y, Leibovici L, Paul M, Eliakim-Raz N. Attitudes towards antibiotic treatment for patients at end of life and in presence of advanced dementia: a survey among health care professionals.
2. **Dishon-Benattar Y**, Gluck Pfeffer I, Lause Mogensen M, Ward LM, Leibovici L, Dagan E, Paul M. Individualization of ecological costs within a computerized decision support system for antibiotic treatment: effects on the system's recommendations and comparison to physicians' behavior.
3. Tiseo G, Margalit I, Ripa M, Borghi V, Green H, Prendki V, Riccardi N, **Dishon Y**, Perego Giovanni B, Grembiale A, Tinelli M, Castagna A, Mussini C, Yahav D, Paul M, Falcone M, from the ESCMID Study Group for Infections in the Elderly (ESGIE). Predictors of survival in elderly patients with COVID-19 admitted to the hospital: derivation and validation of the FLAMINCOV score.

#### c. Chapters in Scientific collections/books